Cassava Sciences Inc (SAVA) - Total Liabilities
Based on the latest financial reports, Cassava Sciences Inc (SAVA) has total liabilities worth $40.23 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore how fast is Cassava Sciences Inc growing its equity to track the company's year-over-year net asset growth rate.
Cassava Sciences Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Cassava Sciences Inc's total liabilities have evolved over time, based on quarterly financial data. See SAVA FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Cassava Sciences Inc Competitors by Total Liabilities
The table below lists competitors of Cassava Sciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xplus SA
WAR:XPL
|
Poland | zł19.44 Million |
|
Global Self Storage Inc
NASDAQ:SELF
|
USA | $17.41 Million |
|
Chemfab Alkalis Limited
NSE:CHEMFAB
|
India | Rs1.88 Billion |
|
JLS Co.Ltd
KQ:040420
|
Korea | ₩19.77 Billion |
|
Synthaverse S.A.
WAR:SVE
|
Poland | zł177.72 Million |
|
Gamma Nu Inc
KQ:192410
|
Korea | ₩61.48 Billion |
|
Pratama Widya Tbk Pt
JK:PTPW
|
Indonesia | Rp99.33 Billion |
|
Sow Good Inc. Common Stock
NASDAQ:SOWG
|
USA | $4.50 Million |
Liability Composition Analysis (1999–2025)
This chart breaks down Cassava Sciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Cassava Sciences Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cassava Sciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cassava Sciences Inc (1999–2025)
The table below shows the annual total liabilities of Cassava Sciences Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $43.95 Million | +271.56% |
| 2024-12-31 | $11.83 Million | -16.67% |
| 2023-12-31 | $14.20 Million | +94.59% |
| 2022-12-31 | $7.29 Million | -43.30% |
| 2021-12-31 | $12.87 Million | +512.71% |
| 2020-12-31 | $2.10 Million | +51.41% |
| 2019-12-31 | $1.39 Million | +171.43% |
| 2018-12-31 | $511.00K | -54.86% |
| 2017-12-31 | $1.13 Million | +70.23% |
| 2016-12-31 | $665.00K | -73.93% |
| 2015-12-31 | $2.55 Million | +200.12% |
| 2014-12-31 | $850.00K | -52.80% |
| 2013-12-31 | $1.80 Million | -95.88% |
| 2012-12-31 | $43.72 Million | -19.88% |
| 2011-12-31 | $54.57 Million | -17.65% |
| 2010-12-31 | $66.26 Million | -10.16% |
| 2009-12-31 | $73.75 Million | -17.27% |
| 2008-12-31 | $89.15 Million | -14.04% |
| 2007-12-31 | $103.71 Million | -20.55% |
| 2006-12-31 | $130.54 Million | -14.36% |
| 2005-12-31 | $152.44 Million | +1855.30% |
| 2004-12-31 | $7.80 Million | +97.32% |
| 2003-12-31 | $3.95 Million | +27.41% |
| 2002-12-31 | $3.10 Million | +23.08% |
| 2001-12-31 | $2.52 Million | +2.74% |
| 2000-12-31 | $2.45 Million | +715.86% |
| 1999-12-31 | $300.59K | -- |
About Cassava Sciences Inc
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassav… Read more